TABLE 2.
Antiviral selectivity of AT-281 against a panel of RNA and DNA virusesa
| Virus | Type | Cell type | EC50 (μM) | CC50 (μM) |
|---|---|---|---|---|
| Chikungunya | RNA | Huh-7 | 54.2 | >100 |
| Eastern equine encephalitis | RNA | Huh-7 | 10.2 | >100 |
| HCV | RNA | Huh-7 | 0.05 | >100 |
| HIV-1 | RNA | CEM-SS | >100 | >100 |
| Influenza A and B | RNA | MDCK | >100 | >100 |
| Respiratory syncytial virus | RNA | HEp2 | >100 | >100 |
| Rhinovirus | RNA | H1-HeLa | >100 | >100 |
| Rift Valley fever | RNA | Huh-7 | >100 | >100 |
| Adenovirus | DNA | Vero | >100 | >100 |
| Herpes simplex-1 | DNA | Vero | >100 | >100 |
a
The activity of AT-281 was measured in infected cells using assays previously described (see Materials and Methods and reference 15) to determine the effective concentration required to inhibit viral replication 50% (EC50) and the threshold concentration required to obtain a perceptible effect on 50% of the cells incubated without virus (CC50).